Baillie Gifford's Recent Transaction with Aehr Test Systems: An In-Depth Analysis

Baillie Gifford significantly reduced its stake in Aehr Test Systems (NASDAQ: AEHR) by 23.06% on September 30, 2025, selling 458,737 shares at $30.11, a move that now positions AEHR as 0.03% of their portfolio. This strategic adjustment by the long-term growth-focused firm occurred as Aehr, a semiconductor test systems provider, is considered modestly overvalued with a current stock price of $20.34 against a GF Value of $16.34, despite strong balance sheet metrics and revenue growth, but negative earnings growth and low profitability. Following the transaction, Aehr's stock declined 32.45%, underscoring market volatility and Baillie Gifford's potential reallocation of resources within its portfolio.

Analysis

Baillie Gifford, a prominent investment firm known for its long-term growth philosophy, significantly reduced its stake in Aehr Test Systems (AEHR) by 23.06% on September 30, 2025, selling 458,737 shares at $30.11. This strategic adjustment decreased AEHR's portfolio weight to 0.03%, signaling a potential capital reallocation by the growth-focused manager. Following this transaction, AEHR's stock experienced a notable 32.45% decline, reflecting negative market sentiment.

Aehr Test Systems, a semiconductor test systems provider, is currently valued at $20.34 per share with a market capitalization of $610.339 million as of November 15, 2025. The stock is considered modestly overvalued, with a Price to GF Value ratio of 1.24 against a GF Value of $16.34. While the company boasts a strong Balance Sheet Rank (8/10) and Altman Z-score (17.78), its low Profitability Rank (4/10) and Piotroski F-Score of 1 present a mixed financial picture.

Despite a strong 3-year revenue growth of 2.90% (Growth Rank 9/10), Aehr's earnings growth over the same period was negative at -29.10%, highlighting challenges in translating revenue expansion into bottom-line profitability. Baillie Gifford's divestment, coupled with the stock's subsequent decline, suggests a reassessment of AEHR's future growth trajectory or valuation.

Key Decisions for Investors

• Investors should carefully evaluate Baillie Gifford's significant reduction in AEHR, considering the firm's long-term growth philosophy and AEHR's "modestly overvalued" status.
• Monitor Aehr Test Systems' profitability closely, given the negative 3-year earnings growth and low Profitability Rank despite strong revenue growth.
• Assess the conflicting financial health indicators, specifically the strong Altman Z-score against the concerning Piotroski F-Score of 1, for potential hidden risks or operational inefficiencies.
• Given the 32.45% stock decline post-transaction and moderately negative sentiment, consider re-evaluating current positions or potential entry points for AEHR.